CITY THERAPEUTICS, INC. (CTY)
City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease. The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
City Therapeutics Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 50.33M shares outstanding
No company description available.
Leadership
Andrew C. Orth
President, CEO & Director
Tracy Zimmermann
Chief Scientific Officer
Baisong Mei
Chief Medical Officer
John Michael Maraganore
Co-Founder & Executive Chair
Employees
--
Country
--
Sector
Healthcare
Website
--
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 ARCH Venture Partners XII, LLC | 10% Owner | Conversion of Derivative | 3.29M | -- | Oct 19, 2026 |
| ARCH Venture Partners XII, LLC | 10% Owner | Conversion of Derivative | 5.48M | -- | Oct 19, 2026 |
| ARCH Venture Partners XII, LLC | 10% Owner | Conversion of Derivative | 2.03M | -- | Oct 19, 2026 |
| ARCH Venture Partners XII, LLC | 10% Owner | Purchase | 170.0K | $3.06M | Oct 19, 2026 |
 NELSEN ROBERT | Director | Conversion of Derivative | 3.29M | -- | Oct 19, 2026 |
| NELSEN ROBERT | Director | Conversion of Derivative | 5.48M | -- | Oct 19, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Raymond Debbane · joint filing· may incl. warrants· filed Oct 2026 | 4.3M | 8.6% | 13G |
 MARAGANORE JOHN Director | 1.5M | 2.9% | FORM 4 |
 ORTH ANDREW C. President & CEO, Director | 1.1M | 2.1% | FORM 4 |
 Trousil Sebastian Chief Operating Officer | 534.5K | 1.1% | FORM 4 |
 Mei Baisong Chief Medical Officer | 228.7K | 0.5% | FORM 4 |
Insiders
- ARCH Venture Partners XII, LLC10% Owner
- NELSEN ROBERTDirector
- MARAGANORE JOHNDirector
- ORTH ANDREW C.President & CEO
- Greene Barry EDirector
- Philip Ron MDirector
- Nochur SaraDirector
- Trousil SebastianChief Operating Officer
- Mei BaisongChief Medical Officer
based on 50.33M shares outstanding
30d Avg
516.08K
60d Avg
516.08K
90d Avg
516.08K